Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome - Summary - MDSpire
Advertisement
Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome
To evaluate the impact of transitioning from dual antiplatelet therapy (DAPT) to ticagrelor monotherapy at 3 months on major adverse cardiovascular events (MACE) and bleeding events in diabetic patients with acute coronary syndrome (ACS) post-PCI, specifically comparing the outcomes of both treatment strategies.
Key Findings:
Transitioning to ticagrelor monotherapy at 3 months did not significantly increase MACE compared to continued DAPT.
Bleeding events were lower in the ticagrelor monotherapy group compared to the DAPT group.
Interpretation:
The study suggests that early transition to ticagrelor monotherapy may be a safe and effective strategy for diabetic patients post-PCI, potentially reducing bleeding risks without compromising cardiovascular outcomes.
Limitations:
Open-label design may introduce bias, potentially affecting the perceived efficacy and safety of treatments.
Short follow-up duration may not capture long-term outcomes, limiting the generalizability of findings.
Conclusion:
Early transition to ticagrelor monotherapy after 3 months of DAPT is associated with comparable cardiovascular safety and reduced bleeding risk in diabetic patients with ACS post-PCI.
